key: cord-1023643-1hs1kziq
authors: Curreli, Francesca; Ahmed, Shahad; Victor, Sofia M. B.; Drelich, Aleksandra; Panda, Siva S.; Altieri, Andrea; Kurkin, Alexander V.; Tseng, Chien-Te K.; Hillyer, Christopher D.; Debnath, Asim K.
title: Discovery of highly potent pancoronavirus fusion inhibitors that also effectively inhibit COVID-19 variants from the UK (Alpha), South Africa (Beta), and India (Delta)
date: 2021-09-17
journal: bioRxiv
DOI: 10.1101/2021.09.03.458877
sha: 75dff6d2c8aba3c693d02f6f5411b8a94bdde5e3
doc_id: 1023643
cord_uid: 1hs1kziq

We report here the discovery of several highly potent small molecules that showed low nM potency against SARS-CoV (IC50: as low as 13 nM), SARS-CoV-2 (IC50: as low as 23 nM), and MERS-CoV (IC50: as low as 76 nM) in pseudovirus based assays with excellent selectivity indices (SI: as high as > 5000) demonstrating their pancoronavirus inhibition. Some compounds also show 100% inhibition of CPE (IC100) at 1.25 µM against an authentic SARS-CoV-2 (US_WA-1/2020). Furthermore, the most active inhibitors also potently inhibited variants of concerns (VOCs), such as the UK (B.1.1.7), South Africa (B.1.351), and Delta variant (B.1.617.2), originated in India. We confirmed that one of the potent inhibitors binds to the prefusion spike protein trimer of SARS-CoV-2 by SPR. Besides, we showed that they inhibit virus-mediated cell-cell fusion. The ADME data of one of the most active inhibitors, NBCoV1, show drug-like properties. In vivo PK of NBCoV1 in rats demonstrated excellent half-life (t1/2) of 11.3 h, mean resident time (MRT) of 14.2 h, and oral bioavailability. We expect the lead inhibitors to pave the way for further development to preclinical and clinical candidates.

worldwide. In addition, vaccine hesitancy is proving to be a major roadblock to getting populations fully vaccinated in many countries [2] [3] [4] . According to the U.S. Census Bureau's Household Pulse Survey, up to 32% of the U.S. population is reluctant to get vaccinated against SARS-CoV-2. Furthermore, "breakthrough" SARS-CoV-2 infections have been reported among people who were fully vaccinated 5, 6 . Therefore, the development of novel drugs to treat or prevent infection is urgently needed. Coronaviruses (CoVs) are positive-sense, enveloped, single-stranded RNA viruses in the family Coronaviridae, which includes two other CoVs that caused major outbreaks in recent years: Severe Acute Respiratory Syndrome coronavirus (SARS-CoV; originated in China in 2003) and the Middle East Respiratory Syndrome coronavirus (MERS-CoV; originated in Saudi Arabia in 2012). Although these outbreaks were severe, they have been eclipsed by the current COVID-19 pandemic. According to data from the Johns Hopkins Coronavirus Resource Center, as of September 10, 2021, there were more than 223 million cases of COVID-19 and 4.6 million deaths due to COVID-19 globally. In the U.S., over 42 million cases and more than 655,000 deaths have been reported.

Although one broad-spectrum antiviral, remdesivir, was approved by the FDA to be repurposed for emergency use against COVID-19, it has shown limited efficacy in most clinical 6 B.1.617.2 India (Delta). The lead inhibitors are expected to pave the way for further development to preclinical and clinical candidates.

Spike protein of coronaviruses plays a critical role in virus binding to a cellular receptor, subsequent fusion, and entry into host cells, allowing the release of the genetic material for continuing its life cycle. The fusion protein (FP) inserts into the host cell membrane and triggers the formation of a coiled-coil trimer by the heptad repeat region 1 (HR1). The HR2 binds to the trimer's hydrophobic groove in an antiparallel manner, creating a 6-HB, like what was reported for HIV-1 gp41-mediated fusion 36, 37 . However, there is no sequence homology between the HR1 and HR2 of coronaviruses spike protein with HR1 and HR2, respectively, of HIV-1 gp41. The formation of the 6-HB facilitates the virus membrane and host cell membrane to come closer for the fusion process to complete.

The mechanistic similarity between the fusion processes of SARS-CoV and HIV-1 led Jiang et al. to design peptide-based inhibitors with pan-coronavirus activity based on the HR2 domains of SARS-CoV 38 and SARS-CoV-2 25 . Jiang et al. crystallized the postfusion hairpin structure of SARS-CoV-2 (6LXT) 25 and compared that structure with the corresponding SARS-CoV structure (1WYY) 39 reported in 2005. Remarkably, the postfusion hairpin structures were not only structurally similar but also shared critical salt bridges between the HR1 and HR2 regions 25 . Most noteworthy was the finding that in SARS-CoV-2, K947 of the HR1 domain forms a salt bridge with E1182 of the HR2 domain, while in SARS-CoV, K929 of the HR1 domain forms a salt bridge with E1163 of the HR2 domain. Furthermore, even the MERS-CoV postfusion spike structure showed a salt bridge in a similar position-K1021 forms a salt bridge with E1265 40 . We previously reported a similar salt bridge interaction in the HIV-1 gp41 hairpin structure, where K547 of the N-terminal heptad repeat region (also known as HR1) interacts with D632 of the C-terminal heptad repeat region (also known as HR2) 41 . We also reported the design of a series of highly potent, benzoic acid-based inhibitors of HIV-1 gp41 fusion, which contain a COOH group 42 .

Also, we showed through computer-based docking that the COOH group of these inhibitors might interrupt the hairpin structure formation by interacting with the K547 and snuggly fitting to the hydrophobic grove created by three NHR regions 42 . These remarkable similarities in the mechanism of virus fusion and involvement of salt bridges in forming the 6-HB in HIV-1 gp41 and coronaviruses lead us to hypothesize that this class of inhibitors may also interrupt the salt bridge formation by fitting in a cavity in the prefusion trimer of coronaviruses thus preventing the 6-HB formation and eventually the fusion of viruses to host cells. Therefore, we screened a set of nine such compounds from our stock and four new analogs (NBCoV15, NBCoV17, NBCoV28, and NBCoV34) against SARS-CoV-2, SARS-CoV, and MERS-CoV spike pseudotyped antiviral assay (Figure 1) . We added the new four analogs to derive a comprehensive structure-activity relationship (SAR). It is noteworthy that recently peptide-8 based pancoronavirus fusion inhibitors were shown to possess potent inhibitory activity against HIV-1, HIV-2, and SIV 43 .

We are aware that the selected inhibitors contain a well-known frequent hitter scaffold, ene-rhodanine, identified as PAINS (Pan Assay INterference compoundS) [44] [45] [46] . However, instead of discarding these molecules as most likely promiscuous, we decided to demonstrate in pain-staking details that this is a privileged scaffold in the context of pancoronavirus inhibition like reported by others 47 .

We prepared SARS-CoV-2, SARS-CoV, and MERS-CoV pseudoviruses capable of single-cycle infection by transfecting HEK293T/17 cells with an HIV-1 Env-deleted proviral backbone plasmid pNL4-3∆Env-NanoLuc and the respective spike plasmid 48 . We then validated the incorporation of the spike proteins in the respective pseudoviruses by Western blot analysis.

We used the SARS Spike Protein Antibody (Novus Biologicals) to immunodetect the spike protein S2 of SARS-CoV-2 and SARS-CoV pseudoviruses (Figure 2a) . Similarly, we used MERS-coronavirus spike protein S2 polyclonal antibody (Invitrogen) to immunodetect the spike protein S2 of the MERS-CoV pseudovirus (Figure 2b) . For SARS-CoV-2, we found a specific band at 80 kDa, which identifies the subdomain S2, and a second band at about 190 kDa, which corresponds to the full-length S protein (S1 + S2), as previously reported 27, 49, 50 . In SARS-CoV pseudovirus lysate, the same antibody detected a lighter band at 80 kDa representing the S2 subunit and a 190 kDa band, which corresponds to the full-length of the spike S protein ( Figure   2a ). Additionally, for MERS-CoV lysates, we identified the subdomain S2 at 75 kDa and the fulllength S protein at about 185 kDa (Figure 2b ) as previously reported 30, 51 . Thus, these analyses confirmed the correct incorporation of the spike proteins in the respective pseudoviruses.

Afterward, we analyzed the correlation of SARS-CoV-2 and SARS-CoV pseudoviruses infection levels with the expression of the hACE2 receptor by infecting three different cell types, 9 which overexpress the ACE2 receptor. We used the human kidney 293T/ACE2 cells, the human fibrosarcoma HT1080/ACE2 cells, the human lung carcinoma cells A549/ACE2, and the respective parental cell types HEK293T cells, HT1080 cells, and A549 cells. We also infected HeLa cells as a control that do not express the hACE2 receptor. The cells were exposed to the same volumes of the supernatant containing the respective pseudoviruses. As expected, we found that both pseudoviruses did not infect the HeLa cells (Figure 2c, 2d) . Similarly, we detected a low level of infection of the parental cell lines HEK293T, HT1080, and A549 with the SARS-CoV-2 pseudovirus compared to the respective related cell types overexpressing the ACE2 receptor. The 293T/ACE2 and HT1080/ACE2 cells supported high levels of SARS-CoV-2 infection. We detected about 8x10 6 RLU and 1.1x10 7 RLU, respectively, which correspond to a 24-fold and 490-fold higher infection than we detected for the parental cell type HEK293T and HT1080, respectively. The infection detected for the A549/ACE2 cells was moderate (about 3.8x10 5 RLU) compared to HT1080/ACE2 and 293T/ACE2 cells and about 13-fold higher than what we detected for the parental cell type A549. For the SARS-CoV infection study, we found similar results. In this case, the 293T/ACE2 and HT1080/ACE2 cells supported higher infection than what we detected for the parental cell types and the A549/ACE2 cell type. Then, we wanted to confirm these results by analyzing the expression levels of the ACE2 receptor in the different cell lines by western blot (Figure 2f ). As shown in Blot 1, we found that ACE2 expression was undetectable in the parental cell lines 293T and HT1080 while it was overexpressed in HT1080/ACE2 cells. A lower amount of ACE2 was detected in the 293T/ACE2 cell lysate than the amounts detected in HT1080/ACE2 cells confirming the infection study findings (Figure   2c ,2d). The lower infection detected in A549/ACE2 cells suggested a lower ACE2 expression in these cells. For this reason, in Blot 2 (Figure 2f) , to visualize the ACE2 expression, we had to load a higher concentration of proteins (75 µg) and use a 2x concentration of antibodies.

These data, taken together, confirmed that SARS-CoV-2 and SARS-CoV pseudoviruses infect the cells through their interaction with the ACE2 receptor.

To analyze the correlation of MERS-CoV pseudovirus infection levels with the DPP4 (CD26) receptor expression, we infected the fibroblast cell line from lung MRC-5 and hepatocyte-derived carcinoma cell line HuH-7; as a control, we also infected HeLa cells that do not express the DPP4 receptor. In this case, the cells were exposed to the same volumes of the 11 supernatant containing the MERS-CoV pseudovirus. We found that the HuH-7 cells supported an 8.6-fold higher level of MERS-CoV infection than the MRC-5 cells. We detected about 2x10 7 RLU and 2.3x10 6 RLU, respectively. We observed no infection of the HeLa cells (Figure 2e) .

The expression levels of the DPP4 receptor in the two cell lines are reported in Blot 3 ( Figure   2f ). These data, taken together, confirmed that the spike proteins were rightly incorporated in the respective pseudoviruses. It also demonstrated that these pseudoviruses infected the cells through their interaction with the respective receptors.

We evaluated the anti-coronavirus activity of the NBCoV small molecules by infecting the three cell types overexpressing the receptor, namely, 293T/ACE2, HT1080/ACE2, and A549/ACE2 cells, with aliquots of the SARS-CoV-2 pseudovirus, which was pretreated with escalating concentrations of the NBCoV small molecules for 30 minutes. We calculated the concentration of NBCoV small molecules required to inhibit 50% (IC 50 ) of SARS-CoV-2 pseudovirus infection, and the results are reported in Table 1 . We demonstrated that most of the NBCoV compounds inhibited SARS-CoV-2 infection with low nanomolar (nM) activity. The only exceptions were NBCoV5 which had micromolar activity (1205 ± 240 nM, 1050 ± 252 nM, and >2000 nM in 293T/ACE2, HT1080/ACE2, and A549/ACE2 cells, respectively), and NBCoV15, used as a control compound without a COOH group in the phenyl ring, which showed no antiviral activity at 2000 nM. Additionally, compounds NBCoV17, NBCoV28, and NBCoV34 at 2000 nM showed no antiviral activity as well. NBCoV1, NCoV2, and NBCoV4 were the most potent compounds. In fact, for NBCoV1, the calculated IC 50 s were in the range of 32.3-63.4 nM, and the selectivity index (SI obtained from the ratio CC 50 /IC 50 ) ranged from 755 -2755; for NBCoV2, the calculated IC 50 s were in the range of 22.8 -58 nM, and the SIs varied from 1630 -> 4000; finally, for NBCoV4 the IC 50 s were in the range of 26 -73 nM, and the SIs ranged from >1370 -> 2096. The NBCoV3 also displayed potent anti-SARS-CoV-2 activity, but the IC 50 s and SIs obtained for the three cell lines were slightly higher than those detected for NBCoV1, NCoV2, and NBCoV4 (IC 50 s: 60.1 -120 and SIs:750 -> 1563). The remaining NBCoV compounds (NBCoV6 -NBCoV9) showed lower potency than NBCoV1 -NBCoV4, as demonstrated by the higher IC 50 s and SIs. We noticed that all the compounds displayed better activity when tested in 293T/ACE2 and HT1080/ACE2 cells than when tested in A549/ACE2 cells and consistently showed an increase of the IC 50 s and SIs. The cytotoxicity (CC 50 ) of the small molecules was assessed in parallel with the inhibition assays (the data is reported in Table 1 ), and these values were used to determine the SIs. As noted, in some cases (HT1080/ACE2 and A549/ACE2 cell lines), the small molecules did not induce any apparent cell toxicity at the highest dose tested ( Table 1) . As expected, when the cells (rather than the virus) were pretreated with the NBCoV compounds for 30 minutes before infection, they did not confer any protection against SARS-CoV-2 infection even at the higher dose used in the assay (2000 nM) ( Table S1 ). The data validate the hypothesis that the target of these compounds is virus-related and not cell-related.

To derive a structure-activity relationship (SAR), we observed that NBCoV2, which does not have any para-substituent in the carboxyphenyl ring, showed the best antiviral potency against SARS-CoV-2. The compounds (NBCoV1, NBCoV4, and NBCoV8) also showed excellent antiviral activity when there is a hydrophobic substituent at the para position of that ring. NBCoV3 has a highly electronegative fluoro atom at the para-position of the carboxyphenyl ring, and it showed somewhat reduced activity compared to NBCoV2 and NBCoV4. A bulkier hydrophobic substituent (-CH 2 CH 3 ) in NBCoV6 showed slightly lower antiviral activity.

Furthermore, a substituent at the ortho position in the carboxy phenyl ring did not tolerate well and showed poor antiviral activity. The introduction of nitrogen in the phenyl ring (pyridine) did not improve the antiviral activity, although the solubility of this molecule may have improved.

Since we hypothesized that the COOH group of these compounds might be interacting with one of the key positively charged residues in the HR1 region to interfere with the 6-HB formation, we tested an analog devoid of the COOH group (NBCoV15). As expected, this molecule showed no antiviral potency at the highest dose tested. We extended the SAR by substituting the phenylethyl group with either no substitution in the rhodanine moiety (NBCoV17 and NBCoV34) or substituting with a smaller hydrophobic group (prop-1-yne, NBCoV28). Furthermore, the position of COOH is also critical. When the COOH group is at the para position of the phenyl 14 ring (NBCoV34), it loses the inhibitory activity. The data, although with few compounds, clearly generated an insightful SAR.

Although NBCoV17 and NBCoV28 contain COOH and Cl groups at the same positions as NBCoV1, they did not show any activity at the highest dose tested. This data underscores the fact that a combination of electronic and appropriate hydrophobic interactions is essential for the antiviral potency of this series of molecules. The mere presence of the ene-rhodanine moiety shows no role in the inhibition process. Similarly, NBCoV34 had a carboxylic group at the para position, had no hydrophobic group attached to the NH of the rhodanine moiety, and showed no inhibition. Suppose the ene-rhodanine scaffold has any role in the antiviral potency through its promiscuous nature, as claimed. In that case, it should have shown potent antiviral activity because the rhodanine scaffold has no steric hindrance to bind non-specifically to 15 random protein targets. Based on the above observations, we only selected the most active inhibitors to test against other coronaviruses.

To assess whether the NBCoV small molecules have pancoronavirus antiviral activity, we tested them against the SARS-CoV pseudovirus ( Table 2 ). We also found that, in this case, the most potent compounds were NBCoV1 -NBCoV4. Compounds NBCoV1 -NBCoV3 had excellent IC 50 s of 13. NBCoV4 had slightly higher IC 50 s in 293T/ACE2 cells and HT1080/ACE2 cells (SI: 509 and >1852, respectively), but it displayed the 2 nd best activity and best SI (>1000) in A549/ACE2 cells compared to NBCoV1 -NBCoV3. NBCoV5 had poor activity against this pseudovirus in the three cell lines tested. Also, compounds, NBCoV6 -NBCoV9, displayed anti-SARS-CoV activity in all cell lines, but clearly, these compounds were less potent and displayed lower consistency than compounds at NBCoV1 -NBCoV4. In the case of SARS-CoV, the SAR followed a similar pattern to what we observed with SARS-CoV-2. This was expected since the amino acid and structural similarity of the S2 domain of the spike protein in these viruses are high.

The NBCoV small molecules were also evaluated against MERS-CoV pseudovirus by infecting the HuH-7 cells and the MRC-5 cells. As reported in Table 3 , we found that yet again, 52 . We found that none of the NBCoV small molecules showed appreciable activity against this control pseudovirus (IC 50 >783 nM) ( Table 4 ). Based on these experiments, the data suggest that their inhibitory activity is specific to the coronaviruses. However, please note that we already mentioned earlier that NBCoV1-NBCoV9 also showed HIV-1 fusion inhibitory activity.

As the next step, the antiviral activity of the NBCoV small molecules was evaluated by exposing Vero E6 cells with the replication-competent authentic virus SARS-CoV-2 (US_WA-1/2020). On the third day, post-infection, the cells were observed under the microscope to evaluate the formation of virus-induced cytopathic effect (CPE). The efficacy of the small molecules was expressed as the lowest concentration capable of completely prevent virusinduced CPE (IC 100 ). We found that NBCoV1 and NBCoV2 were the most efficient compounds 18 in preventing the complete formation of CPEs with an IC 100 of 1.25 µM followed by NBCoV3, NBCoV4, and NBCoV9, which completely prevented the formation of the virus-induced CPEs at 2.5 µM. NBCoV7 and NBCoV8 also prevented the formation of CPEs with an IC 100 of 5 µM, while NBCoV5 and NBCoV6 did not completely prevent the formation of the virus-induced CPE at 10 µM, which was the highest dose used in this assay ( Table 5) . Moreover, when the cells were pretreated for 2 hr before infection, compounds did not show any protection against SARS-CoV-2 infection at the higher dose used in the assay (10 µM) ( Table S1 ). These findings support the results obtained with the single-cycle pseudovirus-based antiviral assays. Table 6) . We introduced the amino acid substitutions into the pSARS-CoV-2-S trunc expression vector. Next, we infected 293T/ACE2 cells with WT and mutant SARS-CoV-2 pseudoviruses in the absence or the presence of NBCoV1 -NBCoV4 small molecules. We used NBCoV5 as a control because of its poor activity against the coronaviruses. . We do not know precisely how these combinations of mutations cause the antiviral potency of NBCoV4 to drop; therefore, more experiments will be necessary to explain these findings. Nevertheless, the compound still retained appreciable antiviral activity against these mutants. NBCoV3 was slightly less efficient against all the mutant pseudoviruses tested, including the WT. In this case, we found a higher IC 50 when tested against the B.1.1.7 UK triple mutant variant (IC 50 of 232 nM). Finally, NBCoV5 had poor/no activity against these variants. These results, taken together, suggest that the NBCoV small molecules maintain their potency against the three mutant SARS-CoV-2 variants tested.

We used Surface Plasmon Resonance (SPR) to determine the binding affinity of two of the most active inhibitors, NBCoV1 and NBCoV2, of SARS-CoV-2. We selected SARS-CoV-2 Spike (trimer) in a prefusion state as we hypothesize that these inhibitors bind to this trimer and prevent the formation of 6-HB, necessary for fusing the virus to cells. We also wanted to test any possible binding of these inhibitors to the SARS-CoV-2 spike S1 subdomains containing the RBD, which binds to the ACE2 receptor on the host cell. This method is useful in measuring the binding constant (K D ) as well as k on (also known as association constant, ka) and k off (also known as dissociation constant, k d ). Small-molecule inhibitors were passed through the chip surface, and the signal changes (in AU) of each inhibitor at varied concentrations were recorded [ Figure 3(a-d) ]. The resulting data were fit to a 1:1 binding model. The binding affinity K D and kinetic parameters k on and k off of the target proteins' interaction with NBCoV1 and NBCoV2 were determined (Figure 3e) . The K D value of NBCoV1 and NBCoV2 were 1.56 and 5.37 µM, respectively, with SARS-CoV-2 spike trimer. However, when these inhibitors were tested against the SARS-CoV-2 S1 subdomain, the K D value of NBCoV1 was ~5-fold higher than when bound to the prefusion S trimer. Similarly, in the case of NBCoV2, the K D value was ~9-fold higher when compared to the K D value against the SARS-CoV-2 prefusion S trimer. The data indicate that these inhibitors most likely bind to the S2 subdomain of the SARS-CoV-2 trimer, although we do not know the exact mode of binding of these inhibitors. However, binding to the S2 makes sense since these inhibitors are expected to be the fusion inhibitors against coronaviruses.

Efficient virus spreading can be achieved by either a cell-free or a cell-associated mode involving direct cell-to-cell contact/fusion 58 . Cell-to-cell fusion mode permits the virus to infect adjacent cells without producing free virus, contributing to tissue damage and inducing syncytia formation. ACE2/SARS-CoV-2 spike interaction and subsequent conformational changes in the spike protein are critical in initiating the fusion of membranes of infected cells with the adjacent cells 59, 60 . Since we have shown that the NBCoV compounds inhibit SARS-CoV-2 and bind to the SARS-CoV-2 prefusion S trimer, we investigated whether our best compounds, NBCoV1, NBCoV2, and NBCoV4, could prevent SARS-CoV-2 mediated cell-to-cell fusion. NBCoV5 was used as a negative control, as we showed that it had no meaningful anti-SARS-CoV-2 activity.

We have set up a new and novel cell-to-cell fusion assay in our laboratory, which uses Jurkat cells expressing the luciferase gene and the SARS-CoV-2 spike wild type-WT as donor cells and 293T/ACE2 as acceptor cells. We chose Jurkat cells because they grow in suspension, and if not fused with the 293T/ACE2 cells, they can easily be removed from the wells by washing twice with PBS. Jurkat cells were pretreated with escalating concentrations of NBCoV compounds for 1 h, then added to the 293T/ACE2 cells and cocultured for 4 h to allow fusion. We found that NBCoV5 only inhibited the SARS-CoV-2 mediated cell-to-cell fusion at the higher dose (68% inhibition at 4 µM) (Figure 4) , while NBCoV1, NBCoV2, and NBCoV4 potently inhibited the cellto-cell fusion even at the lowest dose used in this assay. In fact, at the concentration of 250 nM, NBCoV1, NBCoV2, and NBCoV4 still maintained a 62-79% inhibitory activity of the SARS-CoV-24 2 mediated cell-to-cell fusion suggesting that these NBCoV small molecules interfere with the SARS-CoV-2 Spike-mediated cell-to-cell fusion.

The in vitro assessment of ADME properties in the early stage of drug discovery and development, especially for the pharmaceutical industry, significantly reduced the drug attrition rate in the last two decades 61 . In 1997, the major causes of failure for drugs that advanced to clinical trials were poor ADME properties 62 . Failures in drug development during the later stages can be very costly. Therefore, we also adopted in vitro ADME assessments of our potent pancoronavirus inhibitors early to develop these fusion inhibitors as preclinical candidates.

We have selected one of the best inhibitors, NBCoV1, with potent antiviral activity, low cytotoxicity, and excellent SI for evaluating its ADME properties. Solubility is one of the key properties of a drug and plays a critical role in drug discovery. Therefore, we measured the solubility of the inhibitor in phosphate buffer at pK 7.4. The data in Table 7 indicate that the solubility is NBCoV1 is low. However, there is room for further improvement through saltformation or formulations. Due to the presence of a COOH anion in all potent NBCoV inhibitors, sodium, calcium, and potassium salts can be made to enhance the solubility and dissolution rate. 63, 64 Next, we measured the permeability of NBCoV1 since it plays a vital role in drug absorption in the intestine and its bioavailability. Compounds with low permeability may absorb less and show poor bioavailability. The human epithelial cell line Caco-2 is the most widely used cell line to measure permeability and simulates human intestinal absorption. Therefore, we performed the Caco-2 bidirectional permeability experiment [apical to basolateral (A-B) and basolateral to apical (B-A) across the Caco-2 cell monolayer], which can be used to measure the efflux ratio and predict the human intestinal permeability of orally administered drugs. The data shown in Table 7 indicates that the apparent permeabilities of NBCoV1 are similar to the oral drug propranolol, Papp, 10 -6 cm/s of which was 19.7 (See Supporting Information). We used valspodar, a P-gp substrate, as a positive control to determine whether there was any involvement of active efflux mediated by P-gp. After treatment with 1 µM valspodar, the efflux ratio compared to no valspodar did not change, indicating that the P-gp mediated efflux was not involved.

Next, we examined the metabolic stability of NBCoV1 in the human liver microsome because the liver is the most crucial site of drug metabolism in the body. The clearance data (Cl int ) in Table 7 indicated that NBCoV1 is a low-clearance compound, and it shows a half-life of 112 minutes. It is worthwhile to mention that achieving low clearance is often the goal of a drug discovery project to reduce drug dose, minimize exposure of the drugs in the body to reduce drug-related toxicities, and prolong half-life. Compounds with high clearance values may be cleared rapidly from the body, and the drugs may have a short duration of action and may need multiple dosing. We have also measured the binding of NBCoV1 in human plasma, and Table 7 shows that the inhibitor is >99.5% bound. Although it may look that NBCoV1 has high protein binding, many drugs have >98% plasma protein binding, and higher protein binding does 68, 69 . Therefore, we decided to use this set of eight CYP450 enzymes to determine whether NBCoV1 has any inhibitory effects on this subfamily of enzymes that may cause potential drugdrug interactions (DDI) when co-administered with other treatment agents. DDI is a potential concern for pharmaceutical companies developing drugs and regulatory agencies such as the FDA.

Often the following guideline is used for the CYP inhibition assessment 70 :

IC 50 > 10 µM (CYP inhibition low) < 10 µM (CYP inhibition moderate)

Based on the above classification, NBCoV1 showed low inhibition against CYP2D6, CYP3A, moderate inhibition against CYP1A2, CYP2B6, CYP2C9, and CYP2C19, and high inhibition against only CYP2C8 enzyme ( Table 7) . However, it is worth noting that Walsky et al.

reported the inhibition of 209 drugs, and they classified high inhibition when IC 50 < 1 µM and IC 50 > 10 µM as moderate inhibition. In addition, this group listed felodipine, a hypertensive drug, along with five others as highly potent inhibitors 71 .

Successful drug discovery depends not only on the preclinical efficacy and toxicity profile of a compound but also on the selection of the right candidate with good in vivo pharmacokinetics in animals (rat, dog, etc.) using appropriate dosing routes, such as oral (PO) and intravenous (IV).

We evaluated the PK parameters of two of the most active inhibitors in rats ( Initial identification of antiviral activity was performed against a lentiviral-based pseudotyped virus with spike protein from SARS-CoV-2 using a NanoLuc (luciferase-based) assay. One of the possibilities is that the ene-rhodanines used may directly inhibit the luciferase enzyme. This possibility can be ruled out as out of fourteen compounds tested, only 3-4 showed antiviral potency, although all the compounds contain the same ene-rhodanine scaffold. In neutralization assays, we pre-treated the pseudoviruses with the small molecules for 30 min before the cell infection as the target of our study is the spike protein of SARS-CoV-2. By contrast, when we pre-treated the cells rather than the viruses, we did not detect any inhibition at the higher doses used in the assay (2000 nM) ( Table S1 ). These experiments suggest that 1) our compounds are not affecting the NanoLuc activity and 2) the target of these compounds is virus-related and not cell-related. In 2008, Auld et al. reported the luciferase inhibitory activity of >72,000 diverse molecules collected from a diverse chemical repository. Twenty-six rhodanines were also tested against the luciferase enzyme, and none showed any inhibitory activity 80 . In this work, to explicitly rule out that the antiviral activity of our small molecules was due to the direct inhibition of the NanoLuc and the FLuc reporters, we expressed these enzymes in 293T/17 cells. We incubated the cells lysates with 2000 nM of NBCoV small molecules (4 small molecules with the highest inhibitory activity NBCoV1-4 and two inactive compounds NBCoV5 and NBCoV34) for 10 minutes at 25 °C. As a control, lysates were untreated or treated with the Intracellular TE Nano-Glo® Substrate/Inhibitor (for the NanoLuc reporter) and 100 µM resveratrol 81 (for the FLuc reporter). We found that while the Nanoluc inhibitor ( Figure S1a ) and the FLuc inhibitor ( Figure S1b ) completely blocked the activity of the respective luciferase enzymes, the NBCoV compounds did not affect the activity of these two enzymes ( Figure S1 a   and b) . No significant differences were detected between the untreated controls and the samples treated with the NBCoV small molecules.

The second concern could be that the rhodanines may interfere with the luminescencebased measurements. However, this possibility in our case can be ruled out because we used the same luciferase enzyme in the control experiment with A-MLV-based pseudovirus as we did with cell-cell fusion assay. However, none of the rhodanine derivatives were active against A-MLV pseudovirus. On the contrary, the most active leads in the SARS-CoV-2 pseudovirus assay also showed activity against cell-cell fusion assay.

The most intriguing argument can be made with the assay results with the authentic SARS-CoV-2 virus, where no luciferase was used. The cells (Vero) were also different from those used in a pseudovirus inhibition assay. In addition, in the authentic virus assay, a microscope was used to determine the CPE, a completely different readout method. Also, in this case, when the cells (rather than the virus) were pretreated for 2 hr before infection, compounds did not confer any protection against SARS-CoV-2 infection at the higher dose used in the assay (10 µM) ( Table S1 ). All these concurrent assays firmly establish that the target of the rhodanines is not random but more specific to the spike protein of SARS-CoV-2.

As suggested by the ACS Editors 78 , we went a step further by measuring the direct binding of the most active inhibitors to the target SARS-CoV-2 spike protein by surface plasmon resonance (SPR) method. Since we hypothesized that these inhibitors are expected to bind the HR1 domain of the spike protein and prevent the six-helix bundle formation similar to HIV-1 or other Class I fusion proteins of enveloped viruses, we used a SARS-CoV-2 prefusion S trimer.

Both NBCoV1 and NBCoV2 showed low µM K D . Thus, although these inhibitors showed some binding to the S1 domain, the K D values were 5-9-fold higher. Therefore, this critical study demonstrated that these inhibitors were preferentially bound to the Spike protein's prefusion state and supported our hypothesis. Admittedly, we do not know the exact binding location, but future x-ray or Cryo-EM structure determination with the inhibitors will undoubtedly provide us with a wealth of information.

In 2014, Baell and Walters, in their comments published in Nature, coined enerhodanines as one of the "most insidious" offenders 82 . They also mentioned that this scaffold primarily works through covalent modification and metal complexation. We do not know whether our inhibitors participate through any such mechanisms without any structural information.

However, we will present some experimental evidence to show that the inhibitors bind to the virus part, not the cellular component, most likely not through the ene-rhodanine scaffold. To accomplish our goal, we used two-prong approaches.

-Pseudovirus-base inhibition assay: Entry/fusion inhibitors that target the virus envelope/spike proteins do not show inhibition if added to the cell first, followed by virus addition. We successfully demonstrated that when we incubated compounds with the cells first and then added pseudovirus, none of the compounds showed any inhibition (Table S1) .

However, if we reverse the sequence by pre-incubating the virus with the compound before adding it to the cells, compounds show dose-response inhibition (Tables 1, 2, 3 and 6 ).

-Authentic live SARS-CoV-2 virus: We demonstrated a similar effect with live virus assay ( Table 5) . None of the compounds tested showed any inhibition when first added to the cells (Table S1) .

The above experiments conclusively established that the target of the inhibitors was not the cellular components but the virus itself.

During pseudovirus-based inhibition assay, cellular toxicity was also assessed for each compound without adding any virus. The data in Table 1 and Based on the ACS Editors' recommendation, we demonstrated that "the compound is active at a concentration substantially lower than those producing cellular toxicity" 78 .

Based on the steps outlined by the nine American Chemical Society (ACS) editors to rule out inhibitory activity due to colloidal aggregation 78 , we decided to investigate these compounds further. Based on one of the suggestions by the Editors to use the publicly available filters, we used the online software, Advisor, developed by Shoichet's team at UCSF (http://advisor.bkslab.org/). The software returned with a message that none of the compounds were like any known aggregator in their database (Supporting Information, Figure S2 ).

However, it also alerted that since the molecules are hydrophobic, other appropriate tests should be performed. The authors suggested that if the activity of the aggregation-based inhibitor can be attenuated by small concentrations of nonionic detergent (0.025% Tween-80), the compound is likely an aggregator 83, 84 . Also, a colloidal aggregator mostly exhibits a steep dose-response curve, and it may be precipitated by centrifugation [85] [86] [87] [88] . Due to the different sensitivity of the cells to detergents, we initially performed a cytotoxicity assay with 293T/ACE2 cells in the presence and absence of 0.025% of Tween-80. Unfortunately, we found that even such a low concentration of Tween-80 was inducing significant cytotoxicity ( Figure S3a) .

Moreover, in the presence of 0.025% Tween-80, the infection of 293T/ACE2 cells with SARS-CoV2 pseudovirus was dramatically decreased (Figure S3b ) compared to the infection done in the absence of Tween-80, suggesting that 0.025% of Tween-80 may also be affecting the viral viability along with the cell viability. Then, we decided to perform the neutralization assay using the supernatant of aliquots of NBCoV1, which were centrifuged to eliminate 'eventual' colloidal aggregations. The dose-response obtained with the centrifuged NBCoV1 was very similar to that obtained with the not-centrifuged NBCoV1 (NBCoV1-control) (Figure S3c) . There was no difference in the calculated IC 50 s, which were 50 nM for the NBCoV1-control and 45 nM for the NBCoV1-centrifuged, suggesting that NBCoV1 activity was not due to colloidal aggregation.

Additionally, in 2003 Seidler et al. 89 suggested that potential aggregators can be screened for inhibition of three unrelated enzymes, specifically, ß-lactamase, trypsin, and malate dehydrogenase (MDH), which are highly sensitive to compound aggregation. One of their criteria suggested that it can be considered promiscuous if the compound inhibits all three enzymes. To this end, we evaluated the activity of 6 NBCoV compounds (4 compounds with the highest inhibitory activity NBCoV1-4 and two inactive compounds NBCoV5 and NBCoV34) at 2000 nM against those three enzymes using a colorimetric assay. As shown in Table S2 , we found that the NBCoV compounds had no inhibitory activity against the three enzymes ßlactamase, trypsin, and MDH, indicating that these compounds should not be considered further as aggregators. shows that there is room for further derivatization of the phenylethyl moiety. The direct binding study by SPR confirmed that these molecules bind to the prefusion trimer of the spike protein of SARS-CoV-2 more tightly than the S1 subdomain of the spike protein. Subsequent cell-tocell fusion assay confirmed that these inhibitors efficiently prevent virus-mediated cell-to-cell fusion. We also demonstrated through a series of rationally designed experiments that these inhibitors are not promiscuous but true pancoronavirus inhibitors despite the presence of enerhodanine scaffold, which was termed by some as "frequent hitters". As part of our early drug discovery protocol, we also performed the ADME study. It indicated that the solubility of these inhibitors needs further improvement either through chemical modifications or through salt formation. All other ADME properties measured showed drug-like characteristics. Furthermore, the pharmacokinetic (PK) study in rats demonstrated that NBCoV1 has all the desirable features, including 20% oral availability to be considered for further pre-clinical assessments.

Overall, we discovered a set of novel small-molecule pancoronavirus fusion inhibitors, which are likely candidates with great potential to be developed as therapy of COVID-19 and related coronavirus diseases.

The 

We screened a set of nine 3- We calculated the TCID 50 according to the Spearman-Karber method 94 .

To confirm the incorporation of the respective spike proteins into the SARS-CoV-2, 

The standard live virus-based microneutralization (MN) assay was used [95] [96] [97] 

The evaluation of the cytotoxicity of NBCoV small molecules in the different cell types was performed in parallel with the antiviral activity assay and measured by using the colorimetric 

For the SARS-CoV-2 mediated cell-to-cell fusion assay, we used Jurkat cells which transiently expressed the luciferase gene and stably expressed the SARS-CoV-2 full Spike wildtype (WT) gene from Wuhan-Hu-1 isolate as donor cells and the 293T/ACE2 as acceptor cells.

Briefly, Jurkat cells at 2x10 5 /mL were transfected with 1 µg/mL of SARS-CoV-2 WT expression vector by using 5 µL/mL of FuGene HD and following the manufacturer's instructions. Following 24 h incubation, transfected Jurkat cells were washed and selected for the SARS-CoV-2 spike expression using Blasticidin at a concentration of 10 µg/mL. To rule out cell resistance to the antibiotic, Jurkat cells that were not transfected with the SARS-CoV-2 spike were exposed to the same concentration of Blasticidin in parallel; the culture was depleted entirely in about 14

days. The antibiotic was replaced every four days, and the selection lasted for about 20 days.

On the day before the assay, the 293T/ACE2 were plated in a 96-well cell culture plate at 8x10 4 /well, while the Jurkat cells were washed with PBS to remove the Blasticidin, resuspended at 2x10 5 /mL, and transfected with 1 µg/mL of pFB-Luc expression plasmid DNA using 5 µL/mL of FuGene HD. Following 20 h incubation, the Jurkat cells were washed with PBS, and aliquots of 8x10 4 /well were incubated with escalating concentrations of the NBCoV compounds for 1 h.

Finally, the Jurkat cells were transferred to the respective wells containing the 293T/ACE2 cells.

Additionally, 293T/ACE2 cells cultured with medium with or without the Jurkat cells were included as positive and negative controls, respectively. As an additional control, a set of 293T/ACE2 cells were incubated with Jurkat cells expressing the luciferase gene only (Jurkat-Luc). The plate was spun for 5 minutes at 1500 rpm then incubated for 4 h at 37ºC. The wells were carefully washed twice with 200 µL of PBS to remove the Jurkat cells that did not fuse with the 293T/ACE2 cells. Finally, the cells were lysed to immediately measure the luciferase activity to calculate the percentage of inhibition of the SARS-CoV-2 mediated cell-to-cell fusion.

The binding study of two of the most active small-molecule inhibitors was performed by In vitro ADME Study. Details of the in vitro ADME study and data analyses can be found in the Supporting Information.

In vivo pharmacokinetics in rats. We selected two of the most active inhibitors, NBCoV1 and NBCoV2, to evaluate the pharmacokinetics (PK) in rats. Rats were 11 weeks and 1 day old and weighed between 200-250 grams. A total of twelve (12) Female Sprague Dawley (SD) rats (Charles River Laboratory, USA) were implanted with a jugular vein catheter and were assigned to the study following acclimation for seven (7) days. Rats were divided into four (4) The concentrations of the Test Article in plasma were determined using high-performance liquid chromatography with tandem mass spectrometric detection (LC-MS/MS). Test Agent was isolated by liquid-liquid extraction. A partial aliquot of the supernatant was transferred to a clean 96-well collection plate, evaporated to dryness under nitrogen, and reconstituted with water.

The extracted samples were analyzed using a Sciex 5500 mass spectrometer. The quantitative range of the assay was from 1-2,000 ng/mL.

Analysis of pharmacokinetic parameters -pharmacokinetic parameters were calculated using PkSolver 98 . Graphs were generated using PkSolver.

Additional Methods: (1) Enzyme inhibition assay, (2) Fluorescence/luminescence interference test, and (3) Colloidal aggregation study can be found in the Supporting Information.

Molecular formula strings; Purification and characterization of all newly synthesized and purchased compounds (S1-S24); in vitro ADME (S25-S34); Additional Methods: Enzyme assay S35-S36); Colloidal aggregation study (S36-S37); Table S1 and S2 (S38); Figure 

The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance

Vaccine hesitancy: Not a new phenomenon, but a new threat

The emergence of vaccine hesitancy among upper-class Brazilians: Results from four birth cohorts

Vaccine hesitancy: a generation at risk

Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination

Severe SARS-CoV-2 Breakthrough Reinfection With Delta Variant After Recovery From Breakthrough Infection by Alpha Variant in a Fully Vaccinated Health Worker

CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serumderived polyclonal antibodies

Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Delta variant: What is happening with transmission, hospital admissions, and restrictions?

How the Delta variant achieves its ultrafast spread

Structure, function, and evolution of coronavirus spike proteins

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities

Cell entry mechanisms of SARS-CoV-2

Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus

Domains and functions of spike protein in SARS-Cov-2 in the context of vaccine design

The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex

Kobophenol A inhibits binding of host ACE2 receptor with spike RBD domain of SARS-CoV-2, a lead compound for blocking COVID-19

Rationally designed ACE2-derived peptides inhibit SARS-CoV-2

De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2

Computational design of 25-mer peptide binders of SARS-CoV-2

Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

Stapled peptides based on human angiotensin-converting enzyme 2 (ACE2) potently inhibit SARS-CoV-2 infection in vitro

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors

Coronavirus membrane fusion mechanism offers a potential target for antiviral development

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization

Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs crossneutralization

The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity

SARS-CoV-2 evolution and vaccines: cause for concern?

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Core structure of gp41 from the HIV envelope glycoprotein

Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion

Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

Central ions and lateral asparagine/glutamine zippers stabilize the post-fusion hairpin conformation of the SARS coronavirus spike glycoprotein

Conserved salt bridge between the N-and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition

Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus

Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation

Machine learning distinguishes with high accuracy between pan-assay interference compounds that are promiscuous or represent dark chemical matter

Toward an understanding of pan-assay interference compounds and promiscuity: a structural perspective on binding modes

Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Immunogenicity of a DNA vaccine candidate for COVID-19

Biochemical characterization of middle east respiratory syndrome coronavirus spike protein proteolytic processing

Macropinocytosis is the entry mechanism of amphotropic murine leukemia virus

Coronaviruses as DNA wannabes: a new model for the regulation of RNA virus replication fidelity

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

The variant gambit: COVID-19's next move

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Virus cell-to-cell transmission

Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma

SARS-CoV-2 and SARS-CoV spike-mediated cellcell fusion differ in their requirements for receptor expression and proteolytic activation

An analysis of the attrition of drug candidates from four major pharmaceutical companies

Managing the drug discovery/development interface

Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019

Salts of therapeutic agents: chemical, physicochemical, and biological considerations

Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?

Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation

Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

Cytochrome P450 2B6: function, genetics, and clinical relevance

Cytochrome P450 inhibition

Examination of 209 drugs for inhibition of cytochrome P450 2C8

New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays

A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening

Evolution of assay interference concepts in drug discovery

Gains from the separation of conjoined twins

Computational advances in combating colloidal aggregation in drug discovery

Gains from no real PAINS: Where 'Fair Trial Strategy' stands in the development of multi-target ligands

The ecstasy and agony of assay interference compounds

Nuisance compounds in cellular assays

Characterization of chemical libraries for luciferase inhibitory activity

Resveratrol inhibits firefly luciferase

Chemistry: Chemical con artists foil drug discovery

A detergent-based assay for the detection of promiscuous inhibitors

Effect of detergent on "promiscuous" inhibitors

Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors

A specific mechanism of nonspecific inhibition

Colloidal aggregation causes inhibition of G protein-coupled receptors

Interpreting steep dose-response curves in early inhibitor discovery

Identification and prediction of promiscuous aggregating inhibitors among known drugs

Efficacy and safety

Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range

Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes

Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity

Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche

High potency of a bivalent human VH domain in SARS-CoV-2 animal models

A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein

Passive transfer of a germline-like neutralizing human monoclonal antibody protects transgenic mice against lethal middle east respiratory syndrome coronavirus infection

PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel